Cargando…
Chimeric antigen receptor modified T-cells for cancer treatment
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Chinese Medical Association
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309024/ https://www.ncbi.nlm.nih.gov/pubmed/30603741 http://dx.doi.org/10.1016/j.cdtm.2018.08.002 |